Loading...
•
Dec 31, 2024
Natera Q4 2024 Earnings Report
Estimated Revenue:$406M
+32.5% YoY
Estimated EPS:-$0.489
+34.6% YoY
Key Takeaways
Natera's Q4 2024 revenue increased by 53% year-over-year to $476.1 million, primarily due to higher product revenue. The company processed 792,800 tests in the quarter, up 26.5% from Q4 2023. Gross margin improved to 62.9%, reflecting cost efficiencies. Net loss narrowed to $53.8 million from $78.0 million in the previous year.
Q4 2024 revenue grew 53% to $476.1 million, driven by strong product sales.
Gross margin improved to 62.9% from 51.4% in Q4 2023.
Processed 792,800 tests, up 26.5% year-over-year.
Net loss reduced to $53.8 million from $78.0 million in Q4 2023.
Natera
Natera
Forward Guidance
Natera anticipates strong revenue growth in 2025, with revenue expected to reach between $1.87 billion and $1.95 billion, while maintaining a gross margin of 60% to 64%.
Positive Outlook
- Expected revenue growth to $1.87 billion - $1.95 billion in 2025.
- Gross margin projected to be in the range of 60% to 64%.
- Continued test volume expansion expected to drive revenue growth.
- Ongoing operational efficiencies expected to improve profitability.
- Strong cash position to support future growth and innovation.
Challenges Ahead
- Potential challenges in reimbursement policies could impact revenue.
- Higher R&D expenses expected due to new product investments.
- Competitive pressures in the genetic testing market remain high.
- Regulatory uncertainties could impact future test offerings.
- Macroeconomic conditions may affect healthcare spending and adoption rates.
Loading...
Key Statistics
Market Cap
$23.1B
P/E Ratio
-93.91
Sector
Health Services
Industry
Medical Or Nursing Services
52-Week High
$177
52-Week Low
$113
Tests Processed
792.8K
Tests Accessioned
778.4K
Tests Reported
771.7K
Tests Reported Lab
758.2K